Jpmorgan Chase & CO Eye Point Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EYPT
# of Institutions
150Shares Held
58MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$75.3 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$46.8 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$36.3 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$34.3 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$34.1 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $308M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...